Salazopyrin in rheumatoid arthritis
| Autor: | R S Amos, Linda Walsh, A. P. Crockson, Brian McConkey, E. P. Butler, R. A. Crockson |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Male
Drug Allergy medicine.medical_specialty Neurology media_common.quotation_subject Immunology Arthritis Clinical state Blood Sedimentation Toxicology Gastroenterology Arthritis Rheumatoid Internal medicine medicine Humans Pharmacology (medical) media_common Pharmacology medicine.diagnostic_test business.industry Middle Aged medicine.disease Dermatology Rheumatology Sulfasalazine C-Reactive Protein Erythrocyte sedimentation rate Rheumatoid arthritis Female business |
| Zdroj: | Agents and Actions. 43:202-205 |
| ISSN: | 1420-908X 0065-4299 |
| DOI: | 10.1007/bf01986689 |
| Popis: | After a 12-week preliminary period of observation 32 patients with consistently active rheumatoid arthritis (RA) were treated for up to 22 weeks with salazopyrin. Seven patients could not tolerate the drug. The remaining 25 patients had a marked improvement in subjective clinical state and significant falls in serum C-reactive protein and the erythrocyte sedimentation rate 6 weeks after treatment began. The improvement was maintained after 22 weeks. The results strongly suggest that further trials with this drug in RA are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink